Targeted therapies in urothelial bladder cancer: a disappointing past preceding a bright future?

被引：16

作者：

Hindy, Joya-Rita ^{[1
]}

Souaid, Tarek ^{[1
]}

Kourie, Hampig Raphael ^{[1
,2
]}

Kattan, Joseph ^{[2
]}

机构：

[1] St Joseph Univ, Fac Med, Med Genet Unit, Beirut, Lebanon

[2] St Joseph Univ, Fac Med, Dept Oncol, Beirut, Lebanon

来源：

FUTURE ONCOLOGY | 2019年 / 15卷 / 13期

关键词：

bladder cancer; immunotherapy; targeted therapy; PHASE-II TRIAL; GROWTH-FACTOR RECEPTOR; TRANSITIONAL-CELL CARCINOMA; DOUBLE-BLIND; OPEN-LABEL; 1ST-LINE TREATMENT; 2ND-LINE TREATMENT; SINGLE-ARM; THERAPEUTIC TARGET; KINASE INHIBITOR;

D O I：

10.2217/fon-2018-0459

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Bladder cancer (BC) is the most frequent cancer affecting the urinary tract. With the growing era of targeted therapies around the 2000s, many trials evaluated the efficacy of targeted therapy in advanced BC. However, no approval was given yet to any form of targeted therapy when it comes to BC. The aim of this paper was to report the most pivotal trials that evaluated different families of targeted therapy in the treatment of BC, according to their biomarkers (FGFR3, EGFR, HER2, VEGF and PI3K/AKT/mTOR). The ongoing trials testing targeted therapies in advanced BC were then summarized. Finally, the different immunotherapies approved for this disease and their potential combination with targeted therapy were addressed.

引用

页码：1505 / 1524

页数：20

共 108 条

[1]

[Anonymous], 2017, Cancer Discov, V7, pOF3, DOI 10.1158/2159-8290.CD-NB2017-095

[2]

[Anonymous], J CLIN ONCOL S

[3]

[Anonymous], THE ASCO POST

[4] Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends [J].

Antoni, Sebastien ;

Ferlay, Jacques ;

Soerjomataram, Isabelle ;

Znaor, Ariana ;

Jemal, Ahmedin ;

Bray, Freddie .

EUROPEAN UROLOGY, 2017, 71 (01) :96-108

[5]

Apolo AB, 2017, J CLIN ONCOL S, V34, P4534

[6] EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016 [J].

Babjuk, Marko ;

Boehle, Andreas ;

Burger, Maximilian ;

Capoun, Otakar ;

Cohen, Daniel ;

Comperat, Eva M. ;

Hernandez, Virginia ;

Kaasinen, Eero ;

Palou, Joan ;

Roupret, Morgan ;

van Rhijn, Bas W. G. ;

Shariat, Shahrokh F. ;

Soukup, Viktor ;

Sylvester, Richard J. ;

Zigeuner, Richard .

EUROPEAN UROLOGY, 2017, 71 (03) :447-461

[7] Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido [J].

Balachandran, Vinod P. ;

Cavnar, Michael J. ;

Zeng, Shan ;

Bamboat, Zubin M. ;

Ocuin, Lee M. ;

Obaid, Hebroon ;

Sorenson, Eric C. ;

Popow, Rachel ;

Ariyan, Charlotte ;

Rossi, Ferdinand ;

Besmer, Peter ;

Guo, Tianhua ;

Antonescu, Cristina R. ;

Taguchi, Takahiro ;

Yuan, Jianda ;

Wolchok, Jedd D. ;

Allison, James P. ;

DeMatteo, Ronald P. .

NATURE MEDICINE, 2011, 17 (09) :1094-U99

[8] First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study [J].

Balar, Arjun V. ;

Castellano, Daniel ;

O'Donnell, Peter H. ;

Grivas, Petros ;

Vuky, Jacqueline ;

Powles, Thomas ;

Plimack, Elizabeth R. ;

Hahn, Noah M. ;

de Wit, Ronald ;

Pang, Lei ;

Savage, Mary J. ;

Perini, Rodolfo F. ;

Keefe, Stephen M. ;

Bajorin, Dean ;

Bellmunt, Joaquim .

LANCET ONCOLOGY, 2017, 18 (11) :1483-1492

[9] Phase II Study of Gemcitabine, Carboplatin, and Bevacizumab in Patients With Advanced Unresectable or Metastatic Urothelial Cancer [J].

Balar, Arjun V. ;

Apolo, Andrea B. ;

Ostrovnaya, Irina ;

Mironov, Svetlana ;

Iasonos, Alexia ;

Trout, Alisa ;

Regazzi, Ashley M. ;

Garcia-Grossman, Ilana R. ;

Gallagher, David J. ;

Milowsky, Matthew I. ;

Bajorin, Dean F. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06) :724-730

[10]

Balar AV, 2017, J CLIN ONCOL S, V30, P4581

← 1 2 3 4 5 6 7 8 9 10 →